source
- Experts preview promising triple-negative breast cancer studies for ASCO 2026At the 2026 ASCO Annual Meeting, leading breast cancer specialists highlighted the triple-negative breast cancer (TNBC) abstracts they consider most likely to influence clinical practice. The disc…
- FDA reexamines previously rejected rare cancer therapy amid claims of political interferenceThe FDA has opened a new review of a treatment for a rare form of cancer that it had turned down a few months earlier. The reconsideration arrives as the agency faces fresh allegations that politi…